Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minapharm PharmaceuticalsCAI:MIPH -0.48%49 Debt-to-Equity is 0.72 as of Dec. 2025, which is 12% below its 10-year median of 0.82. GuruFocus rates CAI:MIPH with a GF Score™ of 49/100 and a GF Value™ of E£368.77 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 811 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks worse than 78.42% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Minapharm Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
CAI:MIPH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.66 Med: 0.82 Max: 1.27
Current: 0.72
During the past 5 years, the highest Debt-to-Equity Ratio of Minapharm Pharmaceuticals was 1.27. The lowest was 0.66. And the median was 0.82.
CAI:MIPH's Debt-to-Equity is ranked worse than 78.42% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs CAI:MIPH: 0.72
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Minapharm Pharmaceuticals Debt-to-Equity Related Terms
Minapharm Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals (CAI:MIPH) has a Debt-to-Equity of 0.72 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Minapharm Pharmaceuticals and its competitors. This is 12% below median its historical median of 0.82. Over the past decade, Minapharm Pharmaceuticals' Debt-to-Equity has ranged from 0.66 to 1.27. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #636 out of 811 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Minapharm Pharmaceuticals' Debt-to-Equity too high?
Minapharm Pharmaceuticals' current Debt-to-Equity of 0.72 is 12% below median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 1.27. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Minapharm Pharmaceuticals' value of 0.72 is 157.1% above this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #636 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Minapharm Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #636 out of 811 companies for Debt-to-Equity. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Minapharm Pharmaceuticals' value of 0.72 is 157.1% above this benchmark. Historically, Minapharm Pharmaceuticals' own Debt-to-Equity has ranged from 0.66 to 1.27 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.28, Minapharm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current Debt-to-Equity of 0.72 is 157.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Debt-to-Equity is 0.72, which is 12% below median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£368.77, compared to a current price of E£770.00 — trading 108.8% above its estimated fair value. The current Debt-to-Equity is 0.72, which is 12% below median its 10-year median of 0.82 and 157.1% above the Drug Manufacturers industry median of 0.28. Minapharm Pharmaceuticals' overall GF Score™ is 49/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Debt-to-Equity is 0.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£770.00 is trading 108.8% above its estimated GF Value™ of E£368.77.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Debt-to-Equity: 0.72 (12% below median its 10-year median of 0.82)
GF Value™: E£368.77 vs. price of E£770.00 (108.8% above fair value)
Industry Position: 157.1% above the Drug Manufacturers median (#636 of 811)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
49GF Score
Get the complete analysis for CAI:MIPH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
